168 related articles for article (PubMed ID: 37183966)
1. Ultrasensitive NGS MRD assessment in Ph+ ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1.
Short NJ; Jabbour E; Macaron W; Ravandi F; Jain N; Kanagal-Shamanna R; Patel KP; Loghavi S; Haddad FG; Yilmaz M; Issa GC; Kebriaei P; Kornblau SM; Pelletier S; Flores W; Matthews J; Garris R; Kantarjian H
Am J Hematol; 2023 Aug; 98(8):1196-1203. PubMed ID: 37183966
[TBL] [Abstract][Full Text] [Related]
2. Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies.
Cazzaniga G; De Lorenzo P; Alten J; Röttgers S; Hancock J; Saha V; Castor A; Madsen HO; Gandemer V; Cavé H; Leoni V; Köhler R; Ferrari GM; Bleckmann K; Pieters R; van der Velden V; Stary J; Zuna J; Escherich G; Stadt UZ; Aricò M; Conter V; Schrappe M; Valsecchi MG; Biondi A
Haematologica; 2018 Jan; 103(1):107-115. PubMed ID: 29079599
[TBL] [Abstract][Full Text] [Related]
3. SOHO State of the Art Updates and Next Questions: Update on the Approach to Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
Haddad FG; Jabbour E; Short NJ; Jain N; Kantarjian H
Clin Lymphoma Myeloma Leuk; 2024 May; 24(5):271-276. PubMed ID: 38185587
[TBL] [Abstract][Full Text] [Related]
4. Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Soverini S; Martelli M; Bavaro L; De Benedittis C; Papayannidis C; Sartor C; Sorà F; Albano F; Galimberti S; Abruzzese E; Annunziata M; Russo S; Stulle M; Imovilli A; Bonifacio M; Maino E; Stagno F; Maria Basilico C; Borlenghi E; Fozza C; Mignone F; Minari R; Stella S; Baccarani M; Cavo M; Martinelli G
Br J Haematol; 2021 Apr; 193(2):271-279. PubMed ID: 33403687
[TBL] [Abstract][Full Text] [Related]
5. Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1.
Pfeifer H; Cazzaniga G; van der Velden VHJ; Cayuela JM; Schäfer B; Spinelli O; Akiki S; Avigad S; Bendit I; Borg K; Cavé H; Elia L; Reshmi SC; Gerrard G; Hayette S; Hermanson M; Juh A; Jurcek T; Chillón MC; Homburg C; Martinelli G; Kairisto V; Lange T; Lion T; Mueller MC; Pane F; Rai L; Damm-Welk C; Sacha T; Schnittger S; Touloumenidou T; Valerhaugen H; Vandenberghe P; Zuna J; Serve H; Herrmann E; Markovic S; Dongen JJMV; Ottmann OG
Leukemia; 2019 Aug; 33(8):1910-1922. PubMed ID: 30858550
[TBL] [Abstract][Full Text] [Related]
6. Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients.
Soverini S; De Benedittis C; Polakova KM; Linhartova J; Castagnetti F; Gugliotta G; Papayannidis C; Mancini M; Klamova H; Salvucci M; Crugnola M; Iurlo A; Albano F; Russo D; Rosti G; Cavo M; Baccarani M; Martinelli G
Oncotarget; 2016 Apr; 7(16):21982-90. PubMed ID: 26980736
[TBL] [Abstract][Full Text] [Related]
7. High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse.
Short NJ; Kantarjian H; Ravandi F; Konopleva M; Jain N; Kanagal-Shamanna R; Patel KP; Macaron W; Kadia TM; Wang S; Jorgensen JL; Khoury JD; Yilmaz M; Kebriaei P; Takahashi K; Garcia-Manero G; Daver N; Post SM; Huang X; Kornblau SM; Pelletier S; Flores W; Matthews J; Garris R; Jabbour E
Blood Adv; 2022 Jul; 6(13):4006-4014. PubMed ID: 35533262
[TBL] [Abstract][Full Text] [Related]
8. Combined use of reverse transcriptase polymerase chain reaction and flow cytometry to study minimal residual disease in Philadelphia positive acute lymphoblastic leukemia.
Muñoz L; López O; Martino R; Brunet S; Bellido M; Rubiol E; Sierra J; Nomdedéu JF
Haematologica; 2000 Jul; 85(7):704-10. PubMed ID: 10897122
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of MRD monitoring based on
Arunachalam AK; Janet NB; Korula A; Lakshmi KM; Kulkarni UP; Aboobacker FN; Abraham A; George B; Balasubramanian P; Mathews V
Leuk Lymphoma; 2020 Dec; 61(14):3468-3475. PubMed ID: 32852239
[TBL] [Abstract][Full Text] [Related]
10. Detection of Immunoglobulin Heavy Chain Gene Clonality by Next-Generation Sequencing for Minimal Residual Disease Monitoring in B-Lymphoblastic Leukemia.
Shin S; Hwang IS; Kim J; Lee KA; Lee ST; Choi JR
Ann Lab Med; 2017 Jul; 37(4):331-335. PubMed ID: 28445014
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of next-generation sequencing for measurable residual disease monitoring in three major fusion transcript subtypes of B-precursor acute lymphoblastic leukaemia.
Huang YJ; Chen SH; Liu HC; Jaing TH; Yeh TC; Kuo MC; Lin TL; Chen CC; Wang SC; Chang TK; Hsiao CC; Liang DC; Shih LY
Pathology; 2024 Apr; ():. PubMed ID: 38719770
[TBL] [Abstract][Full Text] [Related]
12. Applicability of droplet digital polymerase chain reaction for minimal residual disease monitoring in Philadelphia-positive acute lymphoblastic leukaemia.
Ansuinelli M; Della Starza I; Lauretti A; Elia L; Siravo V; Messina M; De Novi LA; Taherinasab A; Canichella M; Guarini A; Foà R; Chiaretti S
Hematol Oncol; 2021 Dec; 39(5):680-686. PubMed ID: 34402088
[TBL] [Abstract][Full Text] [Related]
13. Next-generation sequencing for BCR-ABL1 kinase domain mutations in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position paper.
Soverini S; Albano F; Bassan R; Fabbiano F; Ferrara F; Foà R; Olivieri A; Rambaldi A; Rossi G; Sica S; Specchia G; Venditti A; Barosi G; Pane F
Cancer Med; 2020 May; 9(9):2960-2970. PubMed ID: 32154668
[TBL] [Abstract][Full Text] [Related]
14. SOHO State of the Art Updates and Next Questions, Measurable Residual Disease in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
Short NJ; Jabbour E; Kantarjian H
Clin Lymphoma Myeloma Leuk; 2024 Feb; ():. PubMed ID: 38485650
[TBL] [Abstract][Full Text] [Related]
15. Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment.
Scheuring UJ; Pfeifer H; Wassmann B; Brück P; Gehrke B; Petershofen EK; Gschaidmeier H; Hoelzer D; Ottmann OG
Leukemia; 2003 Sep; 17(9):1700-6. PubMed ID: 12970767
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease.
Roberts KG; Pei D; Campana D; Payne-Turner D; Li Y; Cheng C; Sandlund JT; Jeha S; Easton J; Becksfort J; Zhang J; Coustan-Smith E; Raimondi SC; Leung WH; Relling MV; Evans WE; Downing JR; Mullighan CG; Pui CH
J Clin Oncol; 2014 Sep; 32(27):3012-20. PubMed ID: 25049327
[TBL] [Abstract][Full Text] [Related]
17. Use of a high sensitive nanofluidic array for the detection of rare copies of BCR-ABL1 transcript in patients with Philadelphia-positive acute lymphoblastic leukemia in complete response.
Iacobucci I; Lonetti A; Venturi C; Ferrari A; Papayannidis C; Ottaviani E; Abbenante MC; Paolini S; Bresciani P; Potenza L; Parisi S; Cattina F; Soverini S; Russo D; Luppi M; Martinelli G
Leuk Res; 2014 May; 38(5):581-5. PubMed ID: 24630366
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Two Quantitative PCR-Based Assays for Detection of Minimal Residual Disease in B-Precursor Acute Lymphoblastic Leukemia Harboring Three Major Fusion Transcripts.
Huang YJ; Kuo MC; Jaing TH; Liu HC; Yeh TC; Chen SH; Lin TL; Yang CP; Wang PN; Sheen JM; Chang TK; Chang CH; Hu SF; Huang TY; Wang SC; Wu KH; Chiou SS; Hsiao CC; Shih LY
J Mol Diagn; 2021 Oct; 23(10):1373-1379. PubMed ID: 34325057
[TBL] [Abstract][Full Text] [Related]
19. [The monitoring of BCR-ABL mRNA by reverse transcription PCR in patients undergoing allogeneic bone marrow transplantation for acute lymphoblastic leukemia with a positive Philadelphia chromosome].
Román J; Castillejo JA; Jiménez A; Maldonado J; Torres A
Med Clin (Barc); 1999 Dec; 113(20):779-82. PubMed ID: 10680143
[TBL] [Abstract][Full Text] [Related]
20. A new highly sensitive real-time quantitative-PCR method for detection of BCR-ABL1 to monitor minimal residual disease in chronic myeloid leukemia after discontinuation of imatinib.
Kitamura H; Tabe Y; Ai T; Tsuchiya K; Yuri M; Misawa S; Horii T; Kawaguchi A; Ohsaka A; Kimura S
PLoS One; 2019; 14(3):e0207170. PubMed ID: 30835732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
